Overview

Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)

Status:
Completed

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether eculizumab is safe and effective in the treatment of adult patients with plasma therapy-sensitive Atypical Hemolytic-Uremic Syndrome (aHUS).

Phase:

Phase 2

Details

Lead Sponsor:

Alexion Pharmaceuticals

Treatments:

Eculizumab